Paul Lammers, M.D., M.Sc. President and Chief Executive Officer Mirna Therapeutics, Inc.Cancer Research Grant Contract • June 21st, 2017 • Mirna Therapeutics, Inc. • Pharmaceutical preparations
Grant ID: DP140067 Attachment F - Contract AmendmentCancer Research Grant Contract • June 21st, 2017 • Mirna Therapeutics, Inc. • Pharmaceutical preparations
Contract Document F: This Attachment (this “Attachment”), dated as of May 11, 2017, is hereby incorporated into and made a part of that certain CANCER RESEARCH GRANT CONTRACT (“Contract”) effective as of June 1, 2014 by and between the Cancer Prevention and Research Institute of Texas (“CPRIT” or the “INSTITUTE”) and Mirna Therapeutics, Inc. (the “RECIPIENT”). A capitalized term used in this Attachment shall have the meaning given the term in the Contract or in the Attachments to the Contract, unless otherwise defined herein. In the event of a conflict between the provisions of this Attachment and the provisions of the Contract, this Attachment shall control. 1. Mirna hereby provides notice of its intent to terminate that certain Cancer Research Grant Contract by and between CPRIT and Mirna effective as of June 1, 2014 (including any attachments thereto, the (“2014 Contract”) pursuant to Section 8.04 thereof. The termination of the 2014 Contract will be made prior to the Termination Da
LEASE TERMINATION AGREEMENT AND RELEASELease Termination Agreement • June 21st, 2017 • Mirna Therapeutics, Inc. • Pharmaceutical preparations • Texas
THIS LEASE TERMINATION AGREEMENT AND RELEASE (the “Agreement”) is made this 5th day of May, 2017, by and between G&I VII ENCINO TRACE II LP, a Delaware limited partnership with an address of 555 East Lancaster Avenue, Suite 100, Radnor, Pennsylvania 19087 (“Landlord”), and MIRNA THERAPEUTICS, INC., a Delaware corporation with an address of 5707 Southwest Parkway, Building II, Suite 100, Austin, Texas 78735 (“Tenant”).
Grant ID: RP101219 Attachment F - Contract AmendmentContract Amendment • June 21st, 2017 • Mirna Therapeutics, Inc. • Pharmaceutical preparations
Contract Document F: This Attachment (this “Attachment”), dated as of May 11, 2017, is hereby incorporated into and made a part of that certain CANCER RESEARCH GRANT CONTRACT (“Contract”) effective as of August 1, 2010 by and between the Cancer Prevention and Research Institute of Texas (“CPRIT” or the “INSTITUTE”) and Mirna Therapeutics, Inc. (the “RECIPIENT”). A capitalized term used in this Attachment shall have the meaning given the term in the Contract or in the Attachments to the Contract, unless otherwise defined herein. In the event of a conflict between the provisions of this Attachment and the provisions of the Contract, this Attachment shall control. 1. Consistent with Texas Administrative Code, Title 25, Part 11, 703.13, and because no Grant funds were expended during the RECIPIENT’s fiscal year in which the Contract was terminated, Section 4.01 is hereby restated and amended in its entirety as follows: Section 4.01 Record Keeping. The RECIPIENT, each Collaborator and each
